Avatar

Scott Eggener, MD

Professor and Chair, Department of Urology

Languages

English

Education

Fellowship

Urologic Oncology, Memorial Sloan-Kettering Cancer Center, NY, 2007

Degrees

MD, Stanford University, Stanford, CA, 1999
BS, University of Illinois, Urbana, IL, 1994

Residencies

Surgery, Northwestern University, Chicago, IL, 2001
Urology, Northwestern University, Chicago, IL, 2005

Contact Information

Scientific Interests

Dr. Eggener's primary research focus has been on improving the management and outcomes for patients with prostate, kidney, and testicular cancer with specific emphasis on prostate cancer screening, imaging, biomarkers, active surveillance, novel treatment strategies, and optimizing surgical outcomes. This has been through health services research, translational discovery, and clinical trials.

Highlighted Publications

Cooperberg MR, Braun AE, Berlin A, Kibel AS, Eggener SE; CANCER-GG1 Writing Group. When is prostate cancer really cancer? J Natl Cancer Inst. 2025 Mar 1;117(3):402-405. doi: 10.1093/jnci/djae200. PMID: 39350309.

Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Konety BR, Miner M, Moses K, Nissenberg MG, Pinto PA, Salami SS, Souter L, Thompson IM, Lin DW. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening: Erratum. J Urol. 2025 Jul;214(1):111. doi: 10.1097/JU.0000000000004546. Epub 2025 Jun 9. Erratum for: J Urol. 2023 Jul;210(1):46 53. doi: 10.1097/JU.0000000000003491. PMID: 40488244.

Eggener SE, Berlin A, Vickers AJ, Paner GP, Wolinsky H, Cooperberg MR. Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. J Clin Oncol. 2022 Sep 20;40(27):3110 3114. doi: 10.1200/JCO.22.00123. Epub 2022 Apr 18. PMID: 35436144.

Lazarovich A, Vigneswaran H, Palsdottir T, Eklund M, Discacciati A, Nordström T, Hubbard RA, Perlis N, Abern MR, Moreira DM, Yonover P, Chow AK, Watts K, Liss MA, Thoreson GR, Abreu AL, Sonn GA, Plym A, Wiklund F, Grönberg H, Murphy AB, Eggener S. A Comparison of Stockholm, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm Multiethnic SEPTA Trial. J Urol. 2025 May;213(5):590-599. doi: 10.1097/JU.0000000000004437. Epub 2025 Apr 9. Erratum in: J Urol. 2025 Aug;214(2):238. doi: 10.1097/JU.0000000000004584. PMID: 40202133.

Daneshmand S, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA, Kollmannsberger C, Schuckman A, So A, Black P, Bagrodia A, Skinner E, Alemozaffar M, Brand T, Eggener S, Pierorazio P, Stratton K, Nappi L, Nichols C, Luo C, Li M, Hu B. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol. 2023 Jun 1;41(16):3009-3018. doi: 10.1200/JCO.22.00624. Epub 2023 Mar 13. PMID: 36913642